Read by QxMD icon Read

Expert Review of Pharmacoeconomics & Outcomes Research

Haihong Chen, Chenxi Liu, Junjie Liu, Yuqing Tang, Xinping Zhang
BACKGROUND: The research evaluated the impact of intravenous antimicrobial restriction strategy (IARS) on different types of hospitals in China for evidence-based management, for outpatients implemented in 2016. METHODS: Based on panel data on antimicrobial use in 121 tertiary hospitals in Zhejiang, China, segmented regression analysis was used to evaluate the impact of IARS in children's hospitals (CHs), obstetrics and gynecology hospitals (OGHs), women's and children's hospitals (WCHs), traditional Chinese medicine hospitals (TCMHs) and general hospitals (GHs)...
November 11, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
G Tsironis, K Koutsoukos, K Athanasakis, A Tsiara, K Tzannis, M Gerolympou, A Visvikis, G Oikonomopoulos, A Kollia, E Giannopoulou, M Dimitra, E Kostouros, A Papatsoris, A Dellis, K Stravodimos, I Varkarakis, E Samantas, G Aravantinos, N Kentepozidis, C Christodoulou, V Bozionelou, M A Dimopoulos, A Bamias
BACKGROUND: The treatment of Metastatic RCC (mRCC) is mainly systematic and has been revolutionized the last years with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the approval of the first targeted agent. PATIENTS AND METHODS: CRISIS was a retrospective multicenter study reviewing the medical charts of adult patients with histologically or cytologically confirmed mRCC that have received or started 1st-line therapy with any of the approved targeted agents...
November 10, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Eliane Molina Psaltikidis, Everton Nunes da Silva, Maria Luiza Moretti, Plínio Trabasso, Raquel Silveira Bello Stucchi, Francisco Hideo Aoki, Luís Gustavo de Oliveira Cardoso, Christian Cruz Höfling, Luis Felipe Bachur, Danilo da Fontoura Ponchet, Maria Rosa Ceccato Colombrini, Cíntia Soarez Tozzi, Rosana Fins Ramos, Sandra Mara Queiroz Costa, Mariângela Ribeiro Resende
BACKGROUND: Outpatient Parenteral Antimicrobial Therapy (OPAT) has been used for decades in different countries to reduce hospitalization rates, with favorable clinical and economic outcomes. This study assesses the cost-utility of OPAT compared to Inpatient Parenteral Antimicrobial Therapy (IPAT) from the perspective of a public university hospital and the Brazilian National Health System (SUS). METHODS: Prospective study with adult patients undergoing OPAT at an infusion center, compared to IPAT...
October 26, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
M Ruggeri, F R Rolli, L A Kondili, C Drago, F De Solda, C Nappi, A Cicchetti
BACKGROUND: Daclatasvir (DCV) combinated with Sofosbuvir (SOF) has shown good efficacy and safety profile for HCV patients. The aim was to evaluate the cost-effectiveness of DCV/SOF regimen versus HCV alternative treatments for patients who failed to achieve the SVR12 after a first DAA treatment from Italian perspective (PITER cohort). METHODS: A Markov model of HCV chronically infected patients was used to develop two scenarios: 1) DCV+ SOF versus Ledipasvir (LDV)+ SOF in Genotype (Gt)1 and Gt4; 2) DCV+ SOF versus no retreatment option in Gt1, Gt3, and Gt4...
October 23, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Foruhar Moayeri, David Dunt, Ya-Seng Arthur Hsueh, Colleen Doyle
PURPOSE: Depression and anxiety are commonly comorbid in Chronic Obstructive Pulmonary Disease (COPD) and associated with high health services utilization and deterioration of the quality of life. This study evaluated the cost-utility of telephone-based cognitive behavioural therapy (TB-CBT) (experimental arm) in comparison with a placebo-befriending (control arm) program in COPD participants with mild to severe depression and/or anxiety. METHODS: The Assessment of Quality of Life (AQoL-4D) scale was used to conduct the cost-utility analysis...
October 16, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Tuangrat Phodha, Arthorn Riewpaiboon, Kumthorn Malathum, Peter C Coyte
Background - Antimicrobial resistance (AMR) is a major health threat worldwide as it brings about poorer outcomes and places economic burdens to society. This study aims to estimate the economic burdens from nosocomial infections (NI) caused by multi-drug resistant (MDR) bacteria in Thailand. Research design and methods - A retrospective cohort study was conducted at a tertiary hospital over 2011-2012. A multivariate log-linear regression model was used to estimate the excess treatment costs of AMR to those non-AMR patients...
October 15, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Giovanni Cenderello, Lucia Taramasso, Domenico Marra, Patrizia Orcamo, Ambra Pasa, Antonio Di Biagio
OBJECTIVES: This article presents a 3-year budget impact simulation on the effects of a chronic Hepatitis C (HCV) eradication plan in real-life costs incurred by the Regional Health Service in the Liguria Region (in Northern Italy). METHODS: The Liguria Region network performed a prospective 3-year (2017-2019) timeframe horizon trends simulation analysis focusing on management interventions and costs. It involved all the eight prescribing centres in the region, starting from retrospective historical performance data and assuming impact of sustained viral response rates for patients treated for HCV...
October 15, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Panagiotis Petrou
Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a monoclonal antibody, has proved its safety and efficacy in this specific subtype, nevertheless its high cost urges for caution among payers. Areas covered: The scope of this study is to systematically search and critically assess the economic evaluation studies of trastuzumab in patients with early stage Her2+ breast cancer...
October 15, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Jörg Mahlich, Jörn Sindern, Moritz Suppliet
Since 2012, the pharmaceutical reimbursement legislation in Germany has been applying external reference pricing that uses country-specific economic weights for foreign prices. However, the law does not specify technical details. Therefore, we develop a proposal on how national income weights can be taken into consideration. Areas covered: We develop weighting schemes that draw on gross domestic product per capita and adjust for purchasing power parities and exchange rates. In a second step, we populate the weighting schemes with economic data as well as with the price data for a pharmaceutical product (abiraterone acetate)...
October 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Sebastian Himmler, Malina Müller, Dennis Ostwald, Ahmed Seddik, Edin Basic, Eva Hradetzky
BACKGROUND: Patients with non-valvular atrial fibrillation (NVAF) have a five times higher stroke risk. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Apixaban, a non-vitamin K oral anticoagulant (NOAC), has demonstrated better efficacy and safety characteristics than the VKA warfarin in the ARISTOTLE trial. This study aims to quantify the potential societal effects of using apixaban instead of VKA in the German NVAF population from 2017 to 2030...
October 8, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Krittaphas Kangwanrattanakul, Titinun Auamnoy
BACKGROUND: The SF-36v2 is commonly used instrument worldwide. Nevertheless, it lacks the evidence of psychometric testing and health-related quality of life (HRQoL) level among the general Thai population. Therefore, this study aimed to investigate the psychometric performance and to evaluate the HRQoL level and the factors associated with it in the general Thai population. METHODS: Cross-sectional research was conducted with 600 Thai subjects. Various psychometric properties were investigated including ceiling/floor effects, item-scale and scale levels validity using correlations, principal component analysis (PCA), and internal consistency...
October 8, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Aneta Mela, Anna Staniszewska, Witold Wrona, Łukasz A Poniatowski, Janusz Jaroszyński, Maciej Niewada
BACKGROUND: According to the current data, around 1% of the Poland population have epilepsy, which comprises about 400,000 people. This group of patients requires life-long therapy including both drug therapy and hospitalization. The character of the epilepsy has a significant impact on the expenses borne by individual patients, and the prevalence of the disease has a significant impact on the health care system. METHODS: This article aims to measure the direct and indirect costs of epilepsy in Poland estimates for the years 2014-2016 (top-down approach)...
October 6, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ben Fm Wijnen, Ruben Plb Van Engelen, Jan Ostermann, Axel Muhlbacher, Arnolf Fw Hendriks, Rafael Conde, Javier Gr Gonzalez, Mark Jg Govers, Silvia Maa Evers, Mickaël Hiligsmann
BACKGROUND: To assess patients' preferences for HIV testing in Colombia. METHODS: A discrete-choice experiment was used to assess preferences of patients diagnosed with HIV, for HIV testing in two HIV clinics in Bogotá, Colombia. Patients were asked to choose repeatedly between two hypothetical HIV testing options that varied with respect to five attributes: distance to testing site, confidentiality, testing days, sample collection method and the services if HIV positive...
October 3, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Pedro Laires, Karen Kurtyka, Edward A Witt, Ying Qiu, Shengsheng Yu, Kristy Iglay
BACKGROUND: Sulfonylureas (SUs) can help manage type 2 diabetes mellitus, but often have side effects. The objective of this study was to identify factors impacting physicians' decisions to discontinue (DC) or down-titrate (DT) SU therapy. METHODS: 1,026 physicians from the All Global panel were asked to rate level of concern regarding potential reasons for DC or DT on a 7-point Likert scale (1 = not concerned, 7 = extremely concerned). Physicians also provided information regarding treatment decisions from one DC patient, one DT patient, and two current SU users...
September 26, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Adrienne M Gilligan, Jessica Franchino-Elder, Xue Song, Cheng Wang, Caroline Henriques, Amy Sainski-Nguyen, Kathleen Wilson, David M Smith, Stephen Sander
BACKGROUND: This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients initiating oral anticoagulants. METHODS: Adult NVAF patients newly diagnosed and treated with dabigatran, rivaroxaban, or warfarin between 10/01/2010 and 12/31/2014 were identified using MarketScan Commercial and Medicare Supplemental databases...
September 25, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ornella Gonzato, Alessandro Gronchi
No abstract text is available yet for this article.
September 19, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurélie Millier, Olivia Wu
Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding of the value of DOACs relative to vitamin K antagonists (VKAs). Areas covered: A systematic literature review was conducted on the available real-world evidence (RWE) of three DOACs (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients with nonvalvular atrial fibrillation (NVAF)...
September 19, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Antoni Sicras-Mainar, Javier Rejas-Gutiérrez, María Pérez-Paramo, Luis Sánchez-Alvarez, Ruth Navarro-Artieda, Josep Darbà
BACKGROUND: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. OBJECTIVE: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). METHODS: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed...
September 17, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Krittaphas Kangwanrattanakul, Cynthia R Gross, Montaya Sunantiwat, Montarat Thavorncharoensap
BACKGROUND: This study explored whether addition of culture-specific bolt-on dimensions, "interpersonal relationships (IR)" and "activities related to bending knees (AK)", improves the relevance and validity of the EQ-5D among Thai patients with diabetes. METHODS: A cross-sectional study was conducted among 200 diabetic patients. Ceiling/floor effects, known-groups validity and test-retest reliability were evaluated. Hierarchical multiple regressions was performed to evaluate the incremental value of the EQ-THA (EQ-5D-5L+ IR+AK) over the EQ-5D-5L in predicting utility measured by VAS (Visual analog scale)...
September 15, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Jonathan D Campbell, Zoltán Kaló
No abstract text is available yet for this article.
September 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"